Monogenic mutations associated with substance use disorders NOT SNPs (single nucleotide polymorphisms)

Grok 4.3

Answer: There are no established monogenic mutations causally linked to substance use disorders, which remain complex polygenic traits driven primarily by common variants.

Substance use disorders involve multiple genetic and environmental factors, with genome-wide association studies identifying numerous SNPs but rarely implicating single-gene Mendelian mutations. Rare monogenic conditions like certain metabolic enzyme deficiencies can indirectly influence substance metabolism, yet these do not equate to direct causation of addiction phenotypes. Research consistently emphasizes polygenic risk scores over single-gene effects, underscoring the absence of validated monogenic associations that meet strict criteria beyond SNP-level variation.

GPT-5.5

Answer: No well-established monogenic mutations have been definitively linked to substance use disorders when excluding SNPs.

Substance use disorders are complex, polygenic traits influenced by many common variants and environmental factors rather than single-gene mutations. Rare monogenic variants may contribute in specific cases or families, but none have reached consensus as causal drivers distinct from SNPs. Research focuses instead on candidate genes like OPRM1 or DRD2 through association studies, not Mendelian inheritance patterns.

Gemini 3.5 Flash

Answer: While substance use disorders are fundamentally polygenic, rare non-SNP monogenic variations—such as CYP2A6 whole-gene deletions—profoundly influence susceptibility by dramatically altering drug metabolism.

Substance use disorders (SUDs) are classical complex genetic traits, meaning they do not follow Mendelian patterns of inheritance caused by a single causative monogenic mutation. Instead, they typically result from the cumulative effect of hundreds of common genetic variants interacting with environmental factors. However, when explicitly excluding single nucleotide polymorphisms (SNPs), the most significant monogenic influences on SUD risk are structural genetic variations, such as copy number variations (CNVs), gene deletions, and duplications. The most prominent example of a non-SNP monogenic variation affecting SUD risk is the CYP2A6*4 allele, which is a whole-gene deletion of the CYP2A6 enzyme responsible for nicotine metabolism. Individuals who are homozygous for this deletion are unable to metabolize nicotine efficiently, leading to elevated nicotine levels after smoking, side effects like nausea, and a profoundly reduced risk of developing tobacco dependence. Similarly, structural variations in the CYP2D6 gene, such as gene duplications that lead to an ultra-rapid metabolizer phenotype, drastically alter the pharmacokinetics of opioids like codeine (converting it rapidly into morphine). This genetic variation significantly impacts drug response, toxicity, and the subsequent likelihood of abuse. While these structural monogenic variants strongly modulate the physiological response to substances, they function as powerful risk-modifying factors rather than direct determinative causes of the behavioral disorder itself.

Claude Opus 4.7

Answer: There are no well-established truly monogenic (single-gene, Mendelian) mutations that cause substance use disorders (SUDs); SUDs are complex polygenic traits, though rare high-impact coding variants in a handful of genes (e.g., ADH1B, ALDH2, OPRM1, CYP2A6, CYP2D6, MAOA) substantially modify risk for specific substances.

Substance use disorders (SUDs) are paradigmatic complex disorders, with heritability estimates of 40–70% but a genetic architecture composed of many common variants of small effect plus environmental contributors. There is no Mendelian, single-gene 'addiction gene' mutation that segregates in families the way Huntington's disease or cystic fibrosis does. So in the strictest sense, monogenic SUDs do not exist. However, if the question is asking about non-SNP, functional coding/structural variants in single genes that strongly shift risk for a particular SUD, several are well-characterized: • ADH1B (alcohol dehydrogenase 1B): the His48Arg variant (rs1229984), classically described as a missense coding variant, dramatically accelerates ethanol→acetaldehyde conversion and is strongly protective against alcohol use disorder, particularly in East Asian and Jewish populations. • ALDH2 (aldehyde dehydrogenase 2): the Glu504Lys (ALDH2*2, rs671) loss-of-function missense variant causes the 'Asian flush' reaction and is one of the strongest known protective factors against alcohol dependence; homozygotes are almost never alcoholic. • CYP2A6: copy-number variants and gene deletions (CYP2A6*4, *9, *12 alleles) reduce nicotine metabolism, lowering risk of heavy smoking and nicotine dependence. These are structural/CNV variants rather than SNPs. • CYP2D6: copy-number variation (gene duplications, deletions, hybrid alleles with CYP2D7) produces ultrarapid or poor metabolizer phenotypes that influence opioid (codeine, tramadol) response and dependence liability. • OPRM1: the A118G (Asn40Asp, rs1799971) functional missense variant alters mu-opioid receptor signaling and has been associated with opioid and alcohol dependence and naltrexone treatment response. • MAOA: the variable-number tandem repeat (VNTR) in the promoter region — a non-SNP repeat polymorphism — modulates monoamine catabolism and has been linked (via gene–environment interaction) with antisocial behavior and alcohol/substance misuse. • SLC6A3 (DAT1): a 40-bp VNTR in the 3' UTR affects dopamine transporter expression and has been studied in cocaine and alcohol dependence. • SLC6A4 (5-HTT): the 5-HTTLPR insertion/deletion polymorphism (a length variant, not a SNP) influences serotonin transporter expression and has been implicated in alcohol dependence and stress-related substance use. • DRD4: a 48-bp VNTR in exon 3 produces receptor isoforms with different dopamine affinity; the 7-repeat allele has been associated with novelty seeking and several SUDs. Key caveat: all of these are risk-modifying variants in a polygenic context, not Mendelian causes. The only near-deterministic examples (ADH1B*2, ALDH2*2 homozygosity) act as protective rather than causative alleles. If 'monogenic mutations' is interpreted literally as Mendelian causation of SUD, the honest answer is that none have been validated.

Final Summary

The AI Roundtable concludes that while substance use disorders are fundamentally polygenic, specific non-SNP structural variations profoundly influence individual risk. Gemini 3.5 Flash and Claude Opus 4.7 identify copy-number variants and gene deletions, such as those in CYP2A6 and CYP2D6, as critical monogenic factors that alter drug metabolism. However, Grok 4.3 and GPT-5.5 maintain that because these variants do not follow a classic Mendelian inheritance pattern, no true monogenic mutations for addiction have been validated.

Models were divided (2 vs 2)